Scarica l'app Stockscreener
1.76
2.76%
-0.05
Dopo l'orario di chiusura:
1.75
-0.01
-0.57%
Precedente Chiudi:
$1.81
Aprire:
$1.82
Volume 24 ore:
22,352
Relative Volume:
0.01
Capitalizzazione di mercato:
$2.61M
Reddito:
-
Utile/perdita netta:
$-7.90M
Rapporto P/E:
-0.00947
EPS:
-185.9263
Flusso di cassa netto:
$-6.29M
1 W Prestazione:
+1.15%
1M Prestazione:
+20.55%
6M Prestazione:
-84.42%
1 anno Prestazione:
-99.57%
Intervallo 1D:
$1.73
$1.8399
Intervallo di 1 settimana:
$1.61
$1.85
Portata 52W:
$1.43
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Nome
Clearmind Medicine Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare CMND vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.76 | 2.57M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Borsa (CMND) Ultime notizie
Why Did CMND Stock Jump 40% Today? - Stocktwits
Clearmind Medicine Company Profile & Introduction - Moomoo
Clearmind Medicine (CMND) Holds Near $1.86 as Biotech Stock Consolidates Within Key RangeFibonacci Extension - vinanet.vn
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial - Benzinga
Clearmind Medicine Receives DSMB Approval to Advance CMND-100 Clinical Trial in Patients With Alcohol Use Disorder - Quiver Quantitative
Clearmind's CMND-100 Will Be Tested in People With Alcohol Use Disorder - Stock Titan
Clearmind Medicine Inc. (NASDAQ:CMND) - intelligentinvestor.com.au
Clearmind Medicine (CMND) holders report 9.99% cap on warrant-based stake - Stock Titan
Clearmind Medicine (CMND) reports intranasal MEAI permeation near 98% in study - Stock Titan
Clearmind Medicine Announces Positive Permeation Results For Intranasal Meai Formulation - TradingView
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery - The Manila Times
Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Program - Quiver Quantitative
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ... - Enidnews.com
Clearmind’s nasal MEAI stays longer on tissue with comparable drug transport - Stock Titan
Clearmind Medicine (CMND) Drops 6.86% to $1.63, Testing Critical Support at $1.55Catalyst Driven Stocks - dars.gov.et
Clearmind Medicine (CMND) Holds Steady at $1.75 as Traders Eye Resistance Near $1.84Wave Equality - vinanet.vn
Clearmind Medicine (Nasdaq: CMND) wins DSMB nod to advance AUD trial - Stock Titan
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study - The Manila Times
CMND-100 Set to Enter Human Testing for Moderate-to-Severe Alcohol Use Disorder - Stock Titan
Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout - Bitget
Clearmind Medicine (CMND) Edges Higher: Biotech Stock Holds Steady Near $1.74 as Support FirmsOvervalued Signals - vinanet.vn
Clearmind Medicine to acquire 51% stake in EV charging firm By Investing.com - Investing.com Nigeria
Clearmind Medicine Signs Letter Of Intent To Acquire 51% Majority Stake In Ev Wireless Charging Solutions For Automated Parking Systems Company - TradingView
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company - The Manila Times
Clearmind Medicine (Nasdaq: CMND) signs LOI for 51% EV charging stake - Stock Titan
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial - The Manila Times
Clearmind completes Part A of FDA-regulated tri... - Pluang
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 - Quiver Quantitative
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - GlobeNewswire Inc.
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine (CMND) Holds Near Support After Marginal DeclineLeveraged ETF Flow - dars.gov.et
Clearmind Medicine (CMND) Stock Forecast & Analyst Ratings - Moomoo
Clearmind Medicine Inc. (CMND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Clearmind files Hong Kong patent for PTSD treatment compounds - Investing.com
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market - The Manila Times
Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
Clearmind's PTSD Filing Targets Market Projected at $30.2B - Stock Titan
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine Inc Azioni (CMND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clearmind Medicine Inc Azioni (CMND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jun 15 '26 |
Sale |
3.32 |
3,183 |
10,568 |
103,492 |
| HRT FINANCIAL LP | 10% Owner |
Jun 12 '26 |
Sale |
3.36 |
2,102 |
7,063 |
106,675 |
| HRT FINANCIAL LP | 10% Owner |
Jun 10 '26 |
Buy |
0.15 |
2,159,052 |
330,335 |
2,063,266 |
| HRT FINANCIAL LP | 10% Owner |
Jun 11 '26 |
Sale |
0.12 |
225,191 |
27,698 |
1,838,075 |
8.37%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):